Cargando…

Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study

Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Becciolini, Andrea, Parisi, Simone, Del Medico, Patrizia, Farina, Antonella, Visalli, Elisa, Molica Colella, Aldo Biagio, Lumetti, Federica, Caccavale, Rosalba, Scolieri, Palma, Andracco, Romina, Girelli, Francesco, Bravi, Elena, Colina, Matteo, Volpe, Alessandro, Ianniello, Aurora, Ditto, Maria Chiara, Nucera, Valeria, Franchina, Veronica, Platè, Ilaria, Donato, Eleonora Di, Amato, Giorgio, Salvarani, Carlo, Bernardi, Simone, Lucchini, Gianluca, De Lucia, Francesco, Molica Colella, Francesco, Santilli, Daniele, Mansueto, Natalia, Ferrero, Giulio, Marchetta, Antonio, Arrigoni, Eugenio, Foti, Rosario, Sandri, Gilda, Bruzzese, Vincenzo, Paroli, Marino, Fusaro, Enrico, Ariani, Alarico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953385/
https://www.ncbi.nlm.nih.gov/pubmed/36830969
http://dx.doi.org/10.3390/biomedicines11020433
Descripción
Sumario:Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for Psoriatic Arthritis (DAPSA) response of apremilast in PsA patients and to analyze the predictors of clinical response. Methods: All PsA consecutive patients treated with apremilast in fifteen Italian rheumatological referral centers were enrolled. Anamnestic data, treatment history, and PsA disease activity (DAPSA) at baseline, 6 months, and 12 months were recorded. The Mann–Whitney test and chi-squared tests assessed the differences between independent groups, whereas the Wilcoxon matched pairs signed-rank test assessed the differences between dependent samples. Logistic regressions verified if there were factors associated with achievement of DAPSA low disease activity or remission at 6 and 12 months. Results: DAPSA low disease activity or remission rates at 6 and 12 months were observed, respectively, in 42.7% (n = 125) and 54.9% (n = 161) patients. Baseline DAPSA was inversely associated with the odds of achieving low disease activity or remission at 6 months (odds ratio (OR) 0.841, 95% confidence interval (CI) 0.804–0.879; p < 0.01) and at 12 months (OR 0.911, 95% CI 0.883–0.939; p < 0.01). Conclusions: Almost half of the PsA patients receiving apremilast achieved DAPSA low disease activity or remission at 6 and 12 months. The only factor associated with achievement of low disease activity or remission at both 6 and 12 months was baseline DAPSA.